AAV with CMV7 promoter driven CreERT2

Name 
AAV-CMV7-CreERT2
Cat No 
VB1502
Availability
3 weeks

This AAV expresses CreERT2 driven by an ubiquitous CMV7 promoter.

The CMV7 promoter is about 0.35 kb in length and is a shortened version of the commonly used CMV promoter. CMV7 has a truncated version of the CMV enhancer. When tested in several cell lines, this promoter provides an expression level that is about 3-5 fold lower than that of the original 0.6Kb CMV promoter.

A mutated form of estrogen ligand-binding domain (ERT2) that binds to synthetic antagonists (such as tamoxifen or its derivative 4-hydroxy-tamoxifen) but not to circulating estrogen, was fused to the Cre recombinase (Cre) to create CreERT2 (also known as “inducible Cre”). When tamoxifen binds to CreERT2, it induces a conformational change of CreERT2, leading to its nuclear translocation, followed by Cre/Lox-mediated recombination.

VB1502
AAV-CMV7-CreERT2

Ready-to-use AAV expressing CreERT2 driven by an ubiquitous CMV7 promoter. Available in AAV1, AAV2, AAV5, AAV6, AAV8, AAV9, AAV-DJ and other serotypes.

Request a Quote

Product Details

AAV Serotype
Available in AAV1, AAV2, AAV3, AAV5, AAV6, AAV8, AAV9, AAV-DJ, AAV-DJ8, AAV-DJ9 and other wildtype/synthetic AAV capsids
AAV ITR
AAV2
Promoter
CMV7 (ubiquitous)
Storage Buffer
PBS/5% Glycerol
Titer
1x10^13 GC/ml
Viral Backbone
Recombinant AAV
Volume (µL)
200

About Storage Conditions

All our viral products should be kept at -80°C. At this temperature, the virus will remain stable for 6-12 months (and in some cases, up to 2 years). Once thawed, the product can be stored at 4°C for 2-3 weeks without significant loss of biological activity. We recommend aliquoting your vectors into low protein binding tubes upon receipt. This helps avoid repeated freeze-thaw cycles, as well as prevent loss of virus. To maintain accurate titer, aliquot in at least 20ul per tube.